Arteriovenous fistula thrombosis, the formation of a blood clot inside a surgically created connection between an artery and a vein used for hemodialysis, is the leading cause of access failure in kidney dialysis patients. In one large ultrasound study, about 12% of patients with hemodialysis vascular access had thrombosis detected, and roughly 60% of those clots were non-occlusive, meaning they partially blocked the vessel rather than shutting it down entirely.1Diagnostic radiology and radiotherapy. Duplex ultrasound of vascular access for hemodialysis thrombosis Because a working fistula is a lifeline for people who depend on dialysis, recognizing the warning signs early and knowing what treatment options exist can make the difference between saving the access and losing it.
Why Clots Form in a Fistula
Most fistula clots trace back to a structural problem inside the vessel. When a vein is surgically connected to an artery, the vein has to adapt to much higher blood flow and pressure than it was designed for. Over time, the inner lining of the vessel can thicken in a process called neointimal hyperplasia, gradually narrowing the channel. This stenosis slows blood flow, and sluggish flow is one of the classic triggers for clot formation.2Kidney and Blood Pressure Research. Risk Factors for Arteriovenous Fistula Thrombus Development: A Systematic Review and Meta-Analysis Animal research has shown that early tiny clots on the vessel wall, combined with disturbed blood flow patterns, actually drive the uneven tissue buildup that leads to more narrowing later, creating a self-reinforcing cycle.3PubMed Central. Early thrombus formation is required for eccentric and heterogeneous neointimal hyperplasia under disturbed flow
But anatomy doesn’t explain everything. Some patients develop clots even without measurable narrowing, while others with significant stenosis go years without a clot. This suggests additional factors at play. One of those is the pattern of shear stress, the friction that flowing blood exerts on the vessel wall. In a study tracking fistulas from the day of surgery through six months, higher wall shear stress on day one was associated with better vein expansion over the following weeks, and the benefit was particularly strong in patients without diabetes.4PubMed Central. Association of Shear Stress with Subsequent Lumen Remodeling in Hemodialysis Arteriovenous Fistulas High oscillatory shear, where blood flow reverses direction instead of flowing smoothly forward, had the opposite effect and was linked to the vessel shrinking instead of expanding.
A case comparison using MRI-based simulations illustrated this vividly. A fistula that eventually failed had lower velocity and wall shear stress on day one compared to a successful one. But by six weeks, the failed fistula’s shear stress had more than doubled while the successful fistula’s had decreased, suggesting that the vessel was struggling to adapt and compensating with abnormally high flow dynamics that ultimately couldn’t be sustained.5Kidney Medicine. Comparison of Arteriovenous Fistulas With Different Patency Outcomes Using Magnetic Resonance Imaging–Based Fluid Structure Interaction Simulations: A Case Report
Risk Factors Beyond the Vessel Itself
Several things happening during dialysis sessions or in the patient’s bloodstream raise the odds of clotting. One of the most well-documented is intradialytic hypotension, the drop in blood pressure that commonly occurs during dialysis. A study in the Journal of the American Society of Nephrology found that patients in the highest quartile of blood-pressure drops during dialysis had roughly double the rate of fistula thrombosis compared to those in the lowest quartile, even after adjusting for baseline blood pressure.6PubMed Central. Intradialytic hypotension and vascular access thrombosis Low blood pressure means less force pushing blood through the fistula, and even brief periods of very slow flow can give a clot a chance to form.
How the fistula is needled for dialysis also matters. Area cannulation, where needles are repeatedly inserted into the same small patch of vein, carries a higher risk of access failure than the rope-ladder technique, which rotates needle sites along the length of the vein. Retrograde needle direction with the bevel facing down has also been linked to increased failure risk.7PubMed Central. Cannulation technique influences arteriovenous fistula and graft survival These details seem minor, but over hundreds of dialysis sessions, needle trauma accumulates and contributes to vessel wall damage and narrowing at the puncture zone.
There’s also the question of inherited or acquired clotting tendencies. A study comparing dialysis patients with and without access thrombosis found that antiphospholipid antibodies were present in roughly half of those with thrombosis, versus under 10% of those without. Activated “sticky” platelet patterns were also more common in the thrombosis group. Interestingly, classic inherited clotting disorders like Factor V Leiden or prothrombin gene mutations were similarly distributed between groups and didn’t seem to drive the difference.8Blood. Recurrent Vascular Access Site Thrombosis in Patients on Hemodialysis – a Problem of Thrombophilia? This suggests that acquired clotting abnormalities, particularly antiphospholipid antibodies, may play a larger role than inherited ones in dialysis access clotting.
Recognizing the Warning Signs
A healthy arteriovenous fistula has a distinctive buzz or vibration you can feel when you place your fingers over it, called a thrill. You can also hear a rushing sound, or bruit, with a stethoscope. When a clot forms, these signs weaken or disappear. In one reported case, the first finding that signaled fistula thrombosis was simply an absent thrill on physical examination.9Kidney International Reports. A FATAL CASE OF AV FISTULA THROMBOSIS ASSOCIATED WITH PULMONARY THROMBOEMBOLISM IN POST RENAL TRANSPLANT PATIENT
Other signs you or your dialysis team might notice include:
- Swelling or hardness: The area over the fistula feels firm and may look swollen, sometimes with visible discoloration.
- Pain or tenderness: Particularly if the clot developed suddenly or the vessel is distended.
- Dialysis difficulties: The machine can’t draw enough blood, or pressures are abnormal during treatment. Sometimes the first clue is that the dialysis session simply doesn’t work.
- Coolness downstream: If the clot is large enough to affect circulation in the limb, the hand on that side may feel cooler than the other.
Checking the thrill daily at home is one of the simplest things you can do. If it’s gone or feels different, contact your dialysis team promptly. Speed matters because a fresh clot is much easier to treat than one that’s been sitting for days and organizing into scar-like tissue.
How Thrombosis Is Diagnosed
Physical examination catches a lot of cases, but duplex ultrasound is the diagnostic method of choice. It combines two types of imaging: one that shows the anatomy of the vessel and another that maps blood flow through it. In a study of 550 hemodialysis patients, duplex ultrasound not only identified which accesses were clotted but also distinguished between partial and complete blockages and helped pinpoint the underlying cause, whether that was stenosis, aneurysm, or something else.1Diagnostic radiology and radiotherapy. Duplex ultrasound of vascular access for hemodialysis thrombosis Ultrasound is non-invasive, doesn’t require contrast dye, and can be done at the bedside or in a vascular lab. When a procedure is planned to remove the clot, angiography (X-ray imaging with contrast injected into the vessel) is typically performed during the procedure itself to get a detailed roadmap.
Endovascular Treatment Options
When a clot is discovered, the first goal is usually to restore flow without surgery if possible. Endovascular approaches, performed through a needle puncture rather than an open incision, have become mainstream. The main techniques fall into a few categories.
Mechanical thrombectomy uses specialized devices inserted through a catheter to physically break up and remove the clot. In a study of vacuum-assisted mechanical thrombectomy, technical success, meaning the clot was cleared, reached about 97%, and clinical success, meaning the patient could actually use the access for dialysis afterward, was about 91%. Six-month primary patency was 71%, and secondary patency, which counts cases where follow-up procedures kept the access working, reached nearly 89%. The average procedure took about 38 minutes.10Journal of Vascular and Interventional Radiology. Safety and Efficacy of a Vacuum-Assisted Mechanical Thrombectomy Device for Acute Dialysis Access Thrombosis
Another approach combines clot aspiration with balloon angioplasty. A catheter is used to suction out the clot, and then a balloon is inflated at any narrowed segments to widen the vessel. One study reported initial success in about 83% of patients, with primary patency around 55% at six months and secondary patency around 75%.11PubMed Central. Percutaneous treatment of thrombosed hemodialysis arteriovenous fistulas: use of thromboaspiration and balloon angioplasty These numbers are lower than the vacuum-assisted device results, which likely reflects differences in patient populations and the evolution of the technology.
Catheter-directed thrombolysis takes a pharmacological approach: a clot-dissolving drug, usually a tissue plasminogen activator (tPA), is delivered directly into the clot through a catheter and left to work over hours. Pulse-spray thrombolysis is a faster variation that forces the drug into the clot under pressure. While procedure success rates can be high (around 95% in one series), the long-term patency results have been mixed, with one study showing only 44% primary patency at 180 days using the pulse-spray technique.12PubMed Central. Outcomes of Catheter-Directed Thrombolysis for Arteriovenous Fistula Thrombosis in Singapore: Is It Still Relevant Today?
Surgical Thrombectomy and How It Compares
Open surgery remains a reliable alternative, especially in specific situations. A Fogarty balloon catheter is inserted into the vessel through a small incision, inflated beyond the clot, and then pulled back to drag the clot out. Surgical thrombectomy is particularly useful for large aneurysmal fistulas where chronic wall-adherent clot needs to be evacuated, and it allows the surgeon to repair other problems, like pseudoaneurysms or ruptured segments, at the same time. Technical success rates range from 70 to 94%, with 12-month patency rates of 68 to 88%.13PubMed Central. Thrombectomy approach for access maintenance in the end stage renal disease population: a narrative review
When endovascular and surgical techniques have been compared directly, the short-term results look similar, with no significant difference in patency rates under 90 days. But meta-analysis data suggest that endovascular thrombectomy has somewhat lower long-term patency at one and two years and higher technical failure rates compared to surgery.13PubMed Central. Thrombectomy approach for access maintenance in the end stage renal disease population: a narrative review In practice, the choice often depends on the specific anatomy of the clotted fistula, what other problems exist alongside the clot, and the expertise available at the treating center.
Data from a Colombian referral center tracking endovascular salvage of native fistulas showed post-intervention primary patency of roughly 65 to 70% at 180 days, declining over time. Cumulative patency, which accounts for repeated interventions, held up better at about 75% at 600 days and 65 to 70% at 1,000 days, eventually falling to around 30% by 1,400 days.14PubMed Central. Endovascular Salvage of Native Arteriovenous Fistulas: Post-Intervention Primary and Cumulative Patency Outcomes in a Colombian Regional Referral Center The message is that most rescued fistulas will need additional interventions over the years, but they can last a surprisingly long time with proactive maintenance.
Complications of Declotting Procedures
Procedures to remove fistula clots are generally safe, but they carry real risks that patients should know about. The most feared complication is pulmonary embolism, where fragments of the clot dislodge during the procedure and travel to the lungs. In rare cases this can be massive and life-threatening. A published case report described cardiac arrest following a massive pulmonary embolism during mechanical declotting, though the patient was resuscitated with tPA.15PubMed. Cardiac arrest following massive pulmonary embolism during mechanical declotting of thrombosed hemodialysis fistula: successful resuscitation with tPA More commonly, complications include hematoma at the access site, vessel perforation, and early re-thrombosis in the hours or days after the procedure. In the vacuum-assisted thrombectomy study mentioned earlier, each of these occurred in about one in 35 patients.
Early re-thrombosis, where the access clots off again within days of a successful procedure, is particularly frustrating. It happened in 6 of 20 patients in one thromboaspiration series and represents one of the unsolved challenges of fistula salvage.11PubMed Central. Percutaneous treatment of thrombosed hemodialysis arteriovenous fistulas: use of thromboaspiration and balloon angioplasty Often, early re-thrombosis points to an underlying stenosis that wasn’t adequately treated during the initial procedure.
Prevention Through Surveillance
The most effective strategy against fistula thrombosis is catching problems before they reach the clotting stage. Regular monitoring of access blood flow, typically done during dialysis using dilution techniques or Doppler measurements, can detect declining flow that suggests developing stenosis. A study found that implementing flow monitoring along with preemptive angioplasty when flow dropped below a threshold reduced thrombosis rates in both native fistulas and synthetic grafts, while also cutting costs by reducing hospitalizations, catheter placements, and missed treatments.16PubMed. Vascular access blood flow monitoring reduces access morbidity and costs
The evidence is stronger for fistulas than for grafts. A meta-analysis of randomized trials found a pooled risk ratio for thrombosis of 0.64 favoring flow monitoring in fistulas alone, but the confidence interval just barely crossed 1.0, and for grafts alone, no benefit was apparent.17PubMed Central. A meta-analysis of randomized clinical trials assessing hemodialysis access thrombosis based on access flow monitoring: where do we stand? Current guidelines generally recommend incorporating blood flow surveillance into routine care for fistulas, while the recommendation is weaker for grafts.18PubMed Central. Hemodialysis vascular access flow surveillance: Current evidence and future directions
Do Blood Thinners Help?
Given that thrombosis is a clotting problem, it’s natural to ask whether anticlotting medications can prevent it. The answer is complicated. A major randomized trial, the Dialysis Access Consortium study, found that clopidogrel reduced early fistula thrombosis by about 37% compared to placebo. The benefit was concentrated in forearm fistulas, with nearly a 50% reduction, while upper-arm fistulas showed no significant benefit. But here’s the catch: despite reducing clots, clopidogrel did not improve the rate of fistulas actually becoming usable for dialysis, meaning the drug prevented clots in some fistulas that were going to fail for other reasons anyway.19American Journal of Kidney Diseases. More Than Reducing Early Fistula Thrombosis Is Required: Lessons From the Dialysis Access Consortium Clopidogrel Fistula Study
A large population-based cohort study painted a somewhat more encouraging picture for antiplatelet agents overall. Aspirin was associated with the strongest reduction in fistula or graft failure, with an adjusted odds ratio of 0.21, meaning about a fivefold lower risk, without an increase in gastrointestinal bleeding. Clopidogrel and dipyridamole also showed protective associations. Warfarin, on the other hand, did not reduce access failure and increased the risk of intracranial hemorrhage.20Journal of Thrombosis and Haemostasis. Preventing arteriovenous shunt failure in hemodialysis patients: a population‐based cohort study These were observational findings, which means they can’t prove cause and effect the way a randomized trial can, but the direction of the evidence is consistent: antiplatelet drugs seem to help, while anticoagulants like warfarin don’t and add bleeding risk.
When the Fistula Can’t Be Saved
Sometimes, despite every effort, a fistula is beyond rescue. Chronic clot, extensive scarring, or repeated failures after intervention mean it’s time to move on. The general approach is to exhaust all options on the same arm before switching sides, and to prefer a new native-vein fistula over a synthetic graft whenever possible. Upper-arm veins, including the cephalic and basilic veins (sometimes requiring surgical transposition to make them accessible), can significantly extend the options for creating another native fistula. Synthetic grafts are reserved for when no suitable native vein exists. Lower-limb and body-wall fistula sites are considered last resort, used only after both upper limbs have been exhausted.21PubMed Central. Hemodialysis vascular access options after failed Brescia-Cimino arteriovenous fistula
While these decisions are being sorted out, a temporary dialysis catheter in a large central vein often bridges the gap. Catheters carry higher infection risks than fistulas and are universally viewed as a last resort for long-term dialysis, which underscores why salvaging an existing fistula is almost always preferred over abandoning it.
The Psychological Side of Access Problems
Something that doesn’t get enough attention is the emotional toll of living with an unpredictable fistula. Dialysis patients have described significant anxiety about whether their access will work at the next session, distress over repeated procedures, and frustration with the visible and physical burden of a fistula on their arm. A qualitative study found that many patients desired psychological support from their healthcare teams, specifically from counselors who understood the unique context of kidney failure, to help them manage the stress and anxiety surrounding vascular access.22Research Connections. Patient perspectives on quality healthcare for hemodialysis vascular access If you’re dealing with access problems and feeling overwhelmed, bringing this up with your dialysis team is reasonable and increasingly recognized as part of good care.
Machine Learning and Predicting Thrombosis Before It Happens
One of the more promising developments is the use of machine learning to predict which patients are most likely to experience fistula thrombosis before it occurs. A recent study developed six different prediction models using routine clinical data and found that a random forest model performed exceptionally well, with an area under the curve of 0.984, which in practical terms means it was very accurate at distinguishing patients who went on to develop thrombosis from those who didn’t. The five features most important for the model’s predictions were the number of prior surgeries, presence of stenosis, free fatty acid levels, platelet count, and C-reactive protein levels.23PubMed Central. Machine learning-based prediction model for arteriovenous fistula thrombosis risk: a retrospective cohort study from 2017 to 2024
Another research group tested five different machine learning approaches and achieved area-under-the-curve values between 0.858 and 0.903 on their test data.24PubMed. Construction of Risk-Prediction Models for Autogenous Arteriovenous Fistula Thrombosis in Patients on Maintenance Hemodialysis These models aren’t in routine clinical use yet, but they point toward a future where a combination of lab values and clinical history could flag high-risk patients weeks or months before a clot forms, allowing preemptive intervention rather than reactive rescue.
Fistula Thrombosis in Children
Pediatric dialysis patients face the same access challenges as adults, but in smaller vessels and growing bodies. A study examining endovascular management of pediatric dialysis access found that technical success was high, at about 99%, but combined six-month primary-assisted and secondary patency was just 42%. For children who needed more than one treatment, the median time to reintervention was about 107 days.25PubMed Central. Safety and Feasibility of Endovascular Management of Pediatric Dialysis Access The procedures appear safe and feasible, but the lower patency numbers compared to adults reflect the particular difficulty of maintaining vascular access in children, where vessel size and growth add layers of complexity. Pediatric patients often require more frequent interventions to keep their access functioning, and transplant remains the strongest long-term solution for children with kidney failure.